Resources

immuno-oncology

Transforming T cell therapy for solid tumors using patient-derived HUB Organoids®

immuno-oncology

Application of HUB Organoids in immuno-oncology drug development

toxicology

HUB Toxicology Organoid Models

organoid screening

10 years of breakthroughs in Organoid Technology: from adult stem cell discovery to changing patients’ lives

Dr. Robert Vries, CEO

Toxicology

A Patient-Derived Organoid Platform to Investigate Gastrointestinal and Liver Toxicities

Dr. Sylvia F. Boj, Chief Scientific Officer

organoid screening

Patient-derived organoids: an emerging platform to de-risk immunotherapy development

Dr. Sylvia F. Boj, Chief Scientific Officer

toxicology

Human kidney patient-derived organoids are a promising tool for modeling drug-induced nephrotoxicity and for assessing preclinical toxicity of immunotherapy

Organoid Technology

Optimization of screening conditions using patient-derived organoids for diagnostic purposes

Organoid Technology

Patient in the lab: Down-scaling patient-derived organoid screening for diagnostic purposes

oncology

Developing a patient-derived organoid biobank, suitable for large-scale drug screenings

immuno-oncology

Autologous organoids and T cell co-cultures as a powerful personalized platform for immunotherapy

immuno-oncology

Tumour organoid and T-cell co-culture assay to evaluate CAR T-cell cytotoxicity

immuno-oncology

Advancing immunotherapy for solid tumors with patient-derived organoids

oncology

Drug discovery to clinical trials in five years

oncology

Accelerating oncology drug discovery with HUB Organoids®

Blog

Ask the Experts – organoid & immune cell co-cultures for immunotherapy

In this post of our "Ask the Experts" series, we provide comprehensive answers to frequently asked questions regarding the practical...

Blog

PDO Screen – Patient-derived Organoids meet Cancer Modeling

Discover how patient-derived organoids can revolutionize oncology research by enabling accurate modeling of tumor biology and predicting patient response to...

Blog

The FDA Modernization Act 2.0: A patient-centric paradigm shift in drug development

Explore what the new legislative bill means for the future of organoid technology in drug development The use of animals...

immuno-oncology

De-risk your immuno-oncology drug development with HUB Organoids®

toxicology

Intestinal organoids as an in vitro platform to characterize disposition, metabolism, and safety profile of small molecules

Eur J Pharm Sci | July 2023

infectious disease

Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma

eLife | July 2021

cystic fibrosis

Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids

J Cyst Fibros | May 2021

inflammatory bowel disease

Organoid-Derived Epithelial Monolayer: A Clinically Relevant In Vitro Model for Intestinal

J Vis Exp | July 2021

oncology

Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients

Cell | May 2015

organoid technology

Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche

Nature | May 2009